The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
The role of the JAK/STAT signal pathway in rheumatoid arthritis
Open accessAbstract
Proinflammatory cytokine activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signal transduction pathway is a critical event in the pathogenesis and progression of rheumatoid arthritis. Under normal conditions, JAK/STAT signaling reflects the influence of negative regulators of JAK/STAT, exemplified by the suppressor of cytokine signaling and protein inhibitor of activated STAT. However, in rheumatoid arthritis (RA) both of these regulators are dysfunctional. Thus, continuous activation of JAK/STAT signaling in RA synovial joints results in the elevated level of matrix metalloproteinase gene expression, increased frequency of apoptotic chondrocytes and most prominently ‘apoptosis resistance’ in the inflamed synovial tissue. Tofacitinib, a JAK small molecule inhibitor, with selectivity for JAK2/JAK3 was approved by the United States Food and Drug Administration (US FDA) for the therapy of RA. Importantly, tofacitinib has demonstrated significant clinical efficacy for RA in the post-US FDA-approval surveillance period. Of note, the success of tofacitinib has spurred the development of JAK1, JAK2 and other JAK3-selective small molecule inhibitors, some of which have also entered the clinical setting, whereas other JAK inhibitors are currently being evaluated in RA clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Tumor necrosis factor signaling
Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401189 · Cited by 2,359
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
Bartok, B., & Firestein, G. S. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00859.x · Cited by 1,906
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Pathogenetic insights from the treatment of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31472-1 · Cited by 1,345
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
SOCS Proteins: Negative Regulators of Cytokine Signaling
Krebs, D. L., & Hilton, D. J. (2001) · STEM CELLS · doi:10.1634/stemcells.19-5-378 · Cited by 827
Cited by
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Methotrexate and its mechanisms of action in inflammatory arthritis
Cronstein, B. N., & Aune, T. M. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0373-9 · Cited by 677
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Ulgen, E., Ozisik, O., & Sezerman, O. U. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00858 · Cited by 469
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
Metadata
- Authors
- Malemud, C. J.
- Venue
- Therapeutic Advances in Musculoskeletal Disease
- Publisher
- SAGE Publications
- Published
- 2018-05-19
- Volume
- 10
- Issue
- 5-6
- Pages
- 117-127
- ISSN
- 1759-720X (ISSN-L)
- 1759-7218
- OpenAlex
- W2803975545
- Cited by
- 302
- References
- 92
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of the JAK/STAT signal pathway in rheumatoid arthritis. https://app.cochat.ai/papers/10.1177/1759720x18776224
- The paper
- Malemud, C. J. (2018). The role of the JAK/STAT signal pathway in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/1759720x18776224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.